Both studies were 12-week, double-blinded, placebo-controlled clinical trials conducted under the regulatory guidelines of Health Canada.
Based on analysis of the data, both the primary and secondary efficacy and safety endpoints were met in both studies.
In February 2010, Welichem had begun enrolling patients in the Phase IIa clinical trial with WBI-1001.
The objectives of the trial were to evaluate the efficacy of the WBI-1001 cream in comparison to the vehicle, and also to evaluate the safety and tolerability of the cream in patients with psoriasis.